ProQR Therapeutics NV (MEX:PRQRN) Other Stockholders Equity: MXN580.8 Mil (As of Mar. 2026)


MEX:PRQRN ProQR Therapeutics NV MEX:PRQRN
44 GF Score
Price MXN36.00
GF Value MXN40.07
! 5 Warning Signs
View Full Analysis

What is ProQR Therapeutics NV Other Stockholders Equity?

ProQR Therapeutics NV MEX:PRQRN 44 Other Stockholders Equity is MXN580.8 Mil as of Mar. 2026. GuruFocus rates MEX:PRQRN with a GF Score™ of 44/100 and a GF Value™ of MXN40.07. The stock has 5 warning signs investors should review.

ProQR Therapeutics NV's Other Stockholders Equity for the quarter that ended in Mar. 2026 was MXN580.8 Mil.

ProQR Therapeutics NV's quarterly Other Stockholders Equity declined from Sep. 2025 (MXN588.1 Mil) to Dec. 2025 (MXN-0.0 Mil) but then increased from Dec. 2025 (MXN-0.0 Mil) to Mar. 2026 (MXN580.8 Mil).

ProQR Therapeutics NV's annual Other Stockholders Equity declined from Dec. 2023 (MXN-0.0 Mil) to Dec. 2024 (MXN-0.0 Mil) and declined from Dec. 2024 (MXN-0.0 Mil) to Dec. 2025 (MXN-0.0 Mil).

ProQR Therapeutics NV Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for ProQR Therapeutics NV's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV Other Stockholders Equity Chart

ProQR Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.00 -0.00 -0.00 -0.00

ProQR Therapeutics NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 575.04 570.57 588.14 -0.00 580.78
MEX:PRQRN
44GF Score
ProQR Therapeutics NV MEX:PRQRN
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProQR Therapeutics NV Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of MXN580.8 Mil mean?
ProQR Therapeutics NV (MEX:PRQRN) has a Other Stockholders Equity of MXN580.8 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on ProQR Therapeutics NV and its competitors.
Is ProQR Therapeutics NV's Other Stockholders Equity too high?
ProQR Therapeutics NV's current Other Stockholders Equity is MXN580.8 Mil. Overall, ProQR Therapeutics NV has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's Other Stockholders Equity compare to GALT and HRTX?
ProQR Therapeutics NV's Other Stockholders Equity of MXN580.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current Other Stockholders Equity is MXN580.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
ProQR Therapeutics NV (MEX:PRQRN) has a current Other Stockholders Equity of MXN580.8 Mil. The stock's GF Value™ is MXN40.07, compared to a current price of MXN36.00 — trading 10.2% below its estimated fair value. The current Other Stockholders Equity is MXN580.8 Mil. ProQR Therapeutics NV's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For ProQR Therapeutics NV (MEX:PRQRN), the current Other Stockholders Equity is MXN580.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ProQR Therapeutics NV (MEX:PRQRN) Overvalued in 2026?

Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued. The current stock price of MXN36.00 is trading 10.2% below its estimated GF Value™ of MXN40.07.

Key valuation signals for MEX:PRQRN:

  • Other Stockholders Equity: MXN580.8 Mil
  • GF Value™: MXN40.07 vs. price of MXN36.00 (10.2% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the MEX:PRQRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ProQR Therapeutics NV Business Description

Other Exchanges PRQR:USA0PQ:Germany
Address Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
44GF Score

Get the complete analysis for MEX:PRQRN

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN36.00
Price
MXN40.07
GF Value